Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease : The International Linked Clinical Trials initiative
In 2011, the UK medical research charity Cure Parkinson's set up the international Linked Clinical Trials (iLCT) committee to help expedite the clinical testing of potentially disease modifying therapies for Parkinson's disease (PD). The first committee meeting was held at the Van Andel Institute in Grand Rapids, Michigan in 2012. This group of PD experts has subsequently met annually to assess and prioritize agents that may slow the progression of this neurodegenerative condition, using a systematic approach based on preclinical, epidemiological and, where possible, clinical data. Over the last 12 years, 171 unique agents have been evaluated by the iLCT committee, and there have been 21 completed clinical studies and 20 ongoing trials associated with the initiative. In this review, we briefly outline the iLCT process as well as the clinical development and outcomes of some of the top prioritized agents. We also discuss a few of the lessons that have been learnt, and we conclude with a perspective on what the next decade may bring, including the introduction of multi-arm, multi-stage clinical trial platforms and the possibility of combination therapies for PD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of Parkinson's disease - (2024) vom: 05. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wyse, Richard K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical trials |
|---|
| Anmerkungen: |
Date Revised 05.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.3233/JPD-230363 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370683188 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370683188 | ||
| 003 | DE-627 | ||
| 005 | 20240406232715.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240406s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3233/JPD-230363 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1367.xml |
| 035 | |a (DE-627)NLM370683188 | ||
| 035 | |a (NLM)38578902 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wyse, Richard K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease |b The International Linked Clinical Trials initiative |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a In 2011, the UK medical research charity Cure Parkinson's set up the international Linked Clinical Trials (iLCT) committee to help expedite the clinical testing of potentially disease modifying therapies for Parkinson's disease (PD). The first committee meeting was held at the Van Andel Institute in Grand Rapids, Michigan in 2012. This group of PD experts has subsequently met annually to assess and prioritize agents that may slow the progression of this neurodegenerative condition, using a systematic approach based on preclinical, epidemiological and, where possible, clinical data. Over the last 12 years, 171 unique agents have been evaluated by the iLCT committee, and there have been 21 completed clinical studies and 20 ongoing trials associated with the initiative. In this review, we briefly outline the iLCT process as well as the clinical development and outcomes of some of the top prioritized agents. We also discuss a few of the lessons that have been learnt, and we conclude with a perspective on what the next decade may bring, including the introduction of multi-arm, multi-stage clinical trial platforms and the possibility of combination therapies for PD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Clinical trials | |
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a disease modification | |
| 650 | 4 | |a drug repurposing | |
| 650 | 4 | |a neuroprotection | |
| 700 | 1 | |a Isaacs, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Barker, Roger A |e verfasserin |4 aut | |
| 700 | 1 | |a Cookson, Mark R |e verfasserin |4 aut | |
| 700 | 1 | |a Dawson, Ted M |e verfasserin |4 aut | |
| 700 | 1 | |a Devos, David |e verfasserin |4 aut | |
| 700 | 1 | |a Dexter, David T |e verfasserin |4 aut | |
| 700 | 1 | |a Duffen, Joy |e verfasserin |4 aut | |
| 700 | 1 | |a Federoff, Howard |e verfasserin |4 aut | |
| 700 | 1 | |a Fiske, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Foltynie, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Greenamyre, J Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Kieburtz, Karl |e verfasserin |4 aut | |
| 700 | 1 | |a Kordower, Jeffrey H |e verfasserin |4 aut | |
| 700 | 1 | |a Krainc, Dimitri |e verfasserin |4 aut | |
| 700 | 1 | |a Matthews, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Darren J |e verfasserin |4 aut | |
| 700 | 1 | |a Mursaleen, Leah |e verfasserin |4 aut | |
| 700 | 1 | |a Schwarzschild, Michael A |e verfasserin |4 aut | |
| 700 | 1 | |a Stott, Simon R W |e verfasserin |4 aut | |
| 700 | 1 | |a Sulzer, David |e verfasserin |4 aut | |
| 700 | 1 | |a Svenningsson, Per |e verfasserin |4 aut | |
| 700 | 1 | |a Tanner, Caroline M |e verfasserin |4 aut | |
| 700 | 1 | |a Carroll, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Simon, David K |e verfasserin |4 aut | |
| 700 | 1 | |a Brundin, Patrik |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Parkinson's disease |d 2013 |g (2024) vom: 05. Apr. |w (DE-627)NLM365873039 |x 1877-718X |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:05 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3233/JPD-230363 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 05 |c 04 | ||